Table 1.
Baseline Characteristics (Safety Population)
| Bazedoxifene | Raloxifene | Placebo | ||
|---|---|---|---|---|
| Characteristic | 20 mg (n = 1886) |
40 mg (n = 1872) |
60 mg (n = 1849) |
(n = 1885) |
| Age, y | ||||
| Mean (SD) | 66.5 (6.5) | 66.2 (6.8) | 66.4 (6.7) | 66.5 (6.8) |
| Ethnic origin, n (%) | ||||
| White | 1657 (87.9) | 1623 (86.7) | 1618 (87.5) | 1641 (87.1) |
| Black | 115 (6.1) | 135 (7.2) | 116 (6.3) | 120 (6.4) |
| Hispanic | 90 (4.8) | 83 (4.4) | 87 (4.7) | 88 (4.7) |
| Othera | 24 (1.3) | 31 (1.7) | 28 (1.5) | 36 (1.9) |
| Years since last menstrual period | ||||
| Mean (SD) | 19.7 (8.6) | 19.3 (8.9) | 19.5 (8.7) | 19.5 (8.8) |
| Hysterectomy, n (%) | 430 (22.8) | 403 (21.5) | 374 (20.2) | 360 (19.1) |
| Type of menopause, n (%) | ||||
| Natural | 1706 (90.5) | 1690 (90.3) | 1700 (91.9) | 1738 (92.2) |
| Surgical oophorectomy | 180 (9.5) | 182 (9.7) | 149 (8.1) | 147 (7.8) |
| Subjects reporting hot flushes, n (%)b | 287 (15.2) | 316 (16.9) | 264 (14.3) | 251 (13.3) |
| Hot flushes per day | ||||
| Mean (SD) | 2.2 (2.4) | 2.1 (2.2) | 1.9 (1.9) | 2.0 (2.1) |
| BMI, kg/m2 | ||||
| Mean (SD) | 26.6 (3.8) | 26.5 (3.9) | 26.4 (3.8) | 26.3 (3.8) |
SD, standard deviation; BMI, body mass index.
aIncludes Asian, Native American, Pacific Islander, and other ethnic origins.
bP < 0.05; Chi-square test.